|1.||Andrei, Graciela: 4 articles (12/2014 - 01/2004)|
|2.||Snoeck, Robert: 4 articles (12/2014 - 01/2004)|
|3.||Boivin, Guy: 4 articles (02/2011 - 04/2002)|
|4.||De Clercq, Erik: 4 articles (12/2006 - 09/2002)|
|5.||Agut, Henri: 3 articles (04/2015 - 11/2009)|
|6.||Prichard, Mark N: 3 articles (12/2014 - 10/2008)|
|7.||Nakao, S: 3 articles (02/2012 - 01/2007)|
|8.||Rovira, Montserrat: 3 articles (01/2011 - 02/2002)|
|9.||Chou, Sunwen: 3 articles (07/2010 - 03/2003)|
|10.||Bredius, Robbert G M: 3 articles (08/2004 - 12/2002)|
08/01/1994 - "Foscarnet has been used successfully in the treatment of limited numbers of immunocompromised patients with CMV-associated gastrointestinal (improvement in over 67% of patients) and other infections. "
12/01/2005 - "Antiviral therapeutic efficacy of foscarnet in hepatitis B virus infection."
11/01/2001 - "Following failure of CDV, foscarnet was effective in controlling the CMV infection in both patients, although the infection recurred in both. "
01/01/1992 - "These findings indicate that foscarnet is an effective first-line treatment for gastrointestinal CMV infection. "
08/01/1986 - "Though topical foscarnet is a safe drug, no appreciable efficacy in treating recurrent genital HSV infection could be shown."
02/14/1992 - "Foscarnet was well tolerated and effective in delaying progression of CMV retinitis in these patients. "
05/01/1989 - "Intermittently administered intravenous foscarnet appears to be an effective, relatively nontoxic therapy for CMV retinitis. "
05/01/1989 - "A pharmacokinetic study was carried out as part of a clinical trial designed to evaluate the safety and efficacy of intermittently administered intravenous foscarnet for the treatment of CMV retinitis. "
01/01/1996 - "Intravenous therapy with foscarnet, guided by the results of the vitreous biopsy, resulted in resolution of the retinitis and an improvement in vision. "
01/01/1992 - "In a randomized comparative trial of immediate and delayed foscarnet treatment utilizing rigorously defined end points, the mean times to retinitis progression were 13.3 weeks among patients receiving immediate foscarnet therapy and 3.2 weeks among those receiving no treatment. "
|3.||Acquired Immunodeficiency Syndrome (AIDS)
06/15/1993 - "Transscleral iontophoresis of foscarnet may provide an effective and safe technique for local treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome."
03/24/1994 - "Efficacy of intravitreal foscarnet in a patient with AIDS."
08/01/1999 - "In the study, 20 patients with advanced stages of AIDS were treated with foscarnet 1% cream five times a day for a mean duration of 34.5 days. "
05/27/1999 - "Crystals in glomerular capillary lumens have also been observed in patients with acquired immunodeficiency syndrome who were treated with foscarnet for cytomegalovirus disease. "
11/01/1998 - "The genetic characterization of a foscarnet-resistant strain of varicella-zoster virus (VZV) that was isolated from a patient with AIDS is reported. "
01/09/1995 - "In light of the previously reported survival benefit seen in patients treated with foscarnet, these data support the use of foscarnet for the initial treatment of cytomegalovirus retinitis."
05/01/1994 - "Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis."
03/01/1994 - "Intravenous foscarnet administration for treatment of cytomegalovirus retinitis."
09/01/1992 - "Recently the Food and Drug Administration approved the drug foscarnet for treatment of cytomegalovirus retinitis. "
11/01/1991 - "Foscarnet approved for cytomegalovirus retinitis."
01/01/2014 - "The patient responded to foscarnet and significant reduction of immunosuppression; she was negative for CMV viremia for the next 12 months. "
01/01/2014 - "Foscarnet-based regimens often eradicated viremia rapidly but were ineffective in the long term and limited by toxicity. "
04/01/1999 - "Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. "
01/01/2014 - "Median viral load half-life and time to viremia eradication among foscarnet-treated patients were 2.6 and 23 days, respectively, and did not correlate with protection from relapse. "
07/01/2003 - "The patient was treated with foscarnet, which led to improvement of the VZV viremia and the hepatic dysfunction. "
|7.||Antiviral Agents (Antivirals)
|9.||DNA (Deoxyribonucleic Acid)
|4.||Transplantation (Transplant Recipients)